Literature DB >> 806016

Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.

W R Shapiro, D F Young, B M Mehta.   

Abstract

The kinetics and distribution of methotrexate in intraventricular and intrathecal cerebrospinal-fluid spaces were studied in patients with meningeal leukemia and meningeal carcinomatosis after drug administration by intravenous infusion, indwelling intraventricular subcutaneous reservoir (Ommaya), or standard lumbar puncture. Negligible ventricular concentrations followed a single intravenous dose. During an intravenous infusion (500 mg per square meter for 24 hours) the ventricular cerebrospinal-fluid concentration rose to 6 times 10-minus 7 M. Methotrexate administered by Ommaya reservoir, at a dose of 6.25 mg per square meter, rapidly distributed in the subarachnoid space; the peak ventricular concentration of 2 times 10-minus 4 M declined exponentially over 48 hours. Lumbar cerebrospinal-fluid concentration reached a maximum of 5 times 10-minus 5 M four hours after injection and then fell exponentially. Administration by lumbar puncture occasionally produced epidural and subdural leakage; even with successful lumbar puncture, ventricular methotrexate concentration varied considerably from patient to patient despite similar doses. Administration by Ommaya reservoir more reliably produced adequate cerebrospinal fluid distribution than administration by lumbar puncture.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 806016     DOI: 10.1056/NEJM197507242930402

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  147 in total

Review 1.  Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis.

Authors:  Stacey L Berg; Marc C Chamberlain
Journal:  Curr Oncol Rep       Date:  2003-01       Impact factor: 5.075

Review 2.  Intrathecal drug administration. Present use and future trends.

Authors:  J S Kroin
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 3.  Leptomeningeal Carcinomatosis in Esophageal Cancer: Case Report and Review of Literature.

Authors:  Amardeep Singh Aulakh; Amanpreet Buttar; Bilal Piperdi
Journal:  J Gastrointest Cancer       Date:  2012-09

4.  Meningeal carcinomatosis.

Authors:  W R Shapiro
Journal:  West J Med       Date:  1991-03

5.  Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center.

Authors:  Samir Dalia; Peter Forsyth; Julio Chavez; Samantha Price; Bijal Shah; Celeste Bello; Lubomir Sokol; Edward Pan; Eduardo Sotomayor; Ji-Hyun Lee; Kate Fisher; Michael Jaglal
Journal:  Int J Hematol       Date:  2014-03-01       Impact factor: 2.490

Review 6.  CNS complications of breast cancer: current and emerging treatment options.

Authors:  Evert C A Kaal; Charles J Vecht
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  Metastatic Complications of Cancer Involving the Central and Peripheral Nervous Systems.

Authors:  Joe S Mendez; Lisa M DeAngelis
Journal:  Neurol Clin       Date:  2018-06-15       Impact factor: 3.806

8.  An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.

Authors:  Kurt A Jaeckle; Tracy Batchelor; Steven J O'Day; Surasak Phuphanich; Pamela New; Glenn Lesser; Allen Cohn; Mark Gilbert; Robert Aiken; Deborah Heros; Lisa Rogers; Eric Wong; Dorcas Fulton; John C Gutheil; Said Baidas; Julia M Kennedy; Warren Mason; Paul Moots; Christy Russell; Lode J Swinnen; Stephen B Howell
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

9.  Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment.

Authors:  Ticiana Leal; Julie E Chang; Minesh Mehta; H Ian Robins
Journal:  Curr Cancer Ther Rev       Date:  2011-11

10.  A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer.

Authors:  E Le Rhun; S Taillibert; F Zairi; N Kotecki; P Devos; A Mailliez; V Servent; L Vanlemmens; P Vennin; T Boulanger; M C Baranzelli; C André; G Marliot; J L Cazin; F Dubois; R Assaker; J Bonneterre; M C Chamberlain
Journal:  J Neurooncol       Date:  2013-03-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.